Prevalence of Abnormal Bone Mineral Density in Hiv-positive Patients in Ibadan, Nigeria

Overview

Journal J West Afr Coll Surg

Specialty General Medicine

Date 2015 Jun 6

PMID 26046022

Citations 6

Authors

T O Alonge

V N Okoje-Adesomoju

O M Atalabi

H A Obamuyide

D Olaleye

I F Adewole

Affiliations

Soon will be listed here.

Abstract

Background: There have been reports of high rate of abnormal bone mineral densities (BMD) among people living with HIV. Following the introduction of combination antiretroviral therapy (CART) into Nigeria, the country is now home to increasing population of HIV positive patients. There is paucity of data about osteoporosis/osteopaenia and bone mineral density in this population.

Aim And Objectives: The aim of the study was to determine the prevalence and determinants of osteopaenia/osteoporosis in a cohort of HIV-positive patients in Nigeria.

Patients And Methods: The BMD of a group of patients attending the outpatient clinic of the University of Ibadan, Nigeria was assessed using a DXA machine. The relationship of bone mineral density to body weight, CART status, protease inhibitor use, and gender was investigated. Their CD4 counts and viral load were also estimated.

Results: A total of 1005 patients participated with a mean age of 41.3 ± 10 years. There were 724 females (72.0%) and 29.7% were single. The median length of diagnosis was 2 years (Range 1-18 years). The Median CD4 count was 371cells/ml and Median viral load was 200 copies/ml. Of this sample, 785 (78.1%) were on CART with 99 (12.6%) on protease inhibitor. The mean body mass index (BMI) was 23.7±4.7 with 9.2% underweight and 10% obese. The prevalence of osteopaenia and osteoporosis were 46.6% and 31.9% respectively, while 19.6% had normal bone mineral density (BMD). Osteoporosis was significantly higher in those aged above 40 years (p= 0.00001), the females (p= 0.022), the single (p=0.028) and the underweight (p=0.0001). There was no significant difference in BMD of those with or without protease inhibitor containing medications as well as treatment naïve patients.

Conclusion: A high prevalence of abnormal bone mineral density was found in HIV positive patients in Nigeria. Patient age above 40 years and a body mass index class of underweight were significant associated factors. Routine bone mineral density assessment is recommended as an adjunct in the evaluation of HIV positive patients in Nigeria.

Citing Articles

Low bone mass in people living with HIV on long-term anti-retroviral therapy: A single center study in Uganda.

Mwaka E, Munabi I, Castelnuovo B, Kaimal A, Kasozi W, Kambugu A PLoS One. 2021; 16(2):e0246389.

PMID: 33544754 PMC: 7864439. DOI: 10.1371/journal.pone.0246389.

Osteoporosis in Africa-where are we now.

Paruk F, Tsabasvi M, Kalla A Clin Rheumatol. 2020; 40(9):3419-3428.

PMID: 32797362 DOI: 10.1007/s10067-020-05335-6.

Physical activity levels among Malawian adults living with HIV and receiving anti-retroviral therapy.

Chisati E, Munthali F, Constantinou D, Lampiao F Malawi Med J. 2020; 32(1):8-12.

PMID: 32733653 PMC: 7366159. DOI: 10.4314/mmj.v32i1.3.

Reduced bone mineral density among HIV infected patients on anti-retroviral therapy in Blantyre, Malawi: Prevalence and associated factors.

Chisati E, Constantinou D, Lampiao F PLoS One. 2020; 15(1):e0227893.

PMID: 31935270 PMC: 6959680. DOI: 10.1371/journal.pone.0227893.

Management of Reduced Bone Mineral Density in HIV: Pharmacological Challenges and the Role of Exercise.

Chisati E, Constantinou D, Lampiao F Front Physiol. 2018; 9:1074.

PMID: 30131721 PMC: 6090029. DOI: 10.3389/fphys.2018.01074.

References

Dube M, Qian D, Edmondson-Melancon H, Sattler F, Goodwin D, Martinez C . Prospective, intensive study of metabolic changes associated with 48 weeks of amprenavir-based antiretroviral therapy. Clin Infect Dis. 2002; 35(4):475-81. DOI: 10.1086/341489. View

Amorosa V, Tebas P . Bone disease and HIV infection. Clin Infect Dis. 2005; 42(1):108-14. DOI: 10.1086/498511. View

Miller P, Zapalowski C, Kulak C, Bilezikian J . Bone densitometry: the best way to detect osteoporosis and to monitor therapy. J Clin Endocrinol Metab. 1999; 84(6):1867-71. DOI: 10.1210/jcem.84.6.5710. View

Altuntas Aydin O, Kumbasar Karaosmanoglu H, Karahasanoglu R, Tahmaz M, Nazlican O . Prevalence and risk factors of osteopenia/osteoporosis in Turkish HIV/AIDS patients. Braz J Infect Dis. 2013; 17(6):707-11. PMC: 9427423. DOI: 10.1016/j.bjid.2013.05.009. View

STEPHENS E, Das R, Madge S, Barter J, Johnson M . Symptomatic osteoporosis in two young HIV-positive African women. AIDS. 2000; 13(18):2605-6. DOI: 10.1097/00002030-199912240-00022. View

Aberg J, Kaplan J, Libman H, Emmanuel P, Anderson J, Stone V . Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2009; 49(5):651-81. DOI: 10.1086/605292. View

Palella Jr F, Delaney K, Moorman A, Loveless M, Fuhrer J, Satten G . Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998; 338(13):853-60. DOI: 10.1056/NEJM199803263381301. View

Glesby M . Bone disorders in human immunodeficiency virus infection. Clin Infect Dis. 2003; 37 Suppl 2:S91-5. DOI: 10.1086/375884. View

. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994; 843:1-129. View

10.

Nolan D, Upton R, McKinnon E, John M, James I, Adler B . Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir. AIDS. 2001; 15(10):1275-80. DOI: 10.1097/00002030-200107060-00009. View

11.

Bonjoch A, Figueras M, Estany C, Perez-Alvarez N, Rosales J, Del Rio L . High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study. AIDS. 2010; 24(18):2827-33. DOI: 10.1097/QAD.0b013e328340a28d. View

12.

Choe P, Choi H, Kim N, Beom Park W, Song K, Bang J . High prevalence of low bone mass and associated factors in Korean HIV-positive male patients undergoing antiretroviral therapy. J Int AIDS Soc. 2014; 17:18773. PMC: 3888902. DOI: 10.7448/IAS.17.1.18773. View

13.

Collin F, Duval X, Moing V, Piroth L, Kaied F, Massip P . Ten-year incidence and risk factors of bone fractures in a cohort of treated HIV1-infected adults. AIDS. 2009; 23(8):1021-4. PMC: 2855855. DOI: 10.1097/QAD.0b013e3283292195. View

14.

Tebas P, Powderly W, Claxton S, Marin D, Tantisiriwat W, Teitelbaum S . Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS. 2000; 14(4):F63-7. PMC: 3170993. DOI: 10.1097/00002030-200003100-00005. View

15.

Brown T, Qaqish R . Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS. 2006; 20(17):2165-74. DOI: 10.1097/QAD.0b013e32801022eb. View

16.

Ammann P, Rizzoli R . Bone strength and its determinants. Osteoporos Int. 2003; 14 Suppl 3:S13-8. DOI: 10.1007/s00198-002-1345-4. View

17.

Qaqish R, Sims K . Bone disorders associated with the human immunodeficiency virus: pathogenesis and management. Pharmacotherapy. 2005; 24(10):1331-46. DOI: 10.1592/phco.24.14.1331.43150. View

18.

Cazanave C, Dupon M, Lavignolle-Aurillac V, Barthe N, Lawson-Ayayi S, Mehsen N . Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. AIDS. 2008; 22(3):395-402. DOI: 10.1097/QAD.0b013e3282f423dd. View

19.

Triant V, Brown T, Lee H, Grinspoon S . Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab. 2008; 93(9):3499-504. PMC: 2567857. DOI: 10.1210/jc.2008-0828. View

20.

Mondy K, Tebas P . Emerging bone problems in patients infected with human immunodeficiency virus. Clin Infect Dis. 2003; 36(Suppl 2):S101-5. DOI: 10.1086/367566. View